Last week, the White House released a comprehensive national strategy to guide federal investments and collaborations with the private sector in the life sciences. The National Bioeconomy Blueprint identifies five strategic objectives that will inform administration efforts to boost the bioeconomy. Key among these objectives is the expansion of foundational, cross-disciplinary research, which will require improved funding mechanisms that are flexible enough to support many kinds of collaborations and that encourage high-risk/high-reward research.

In a new report, the National Academies' Institute of Medicine (IOM) praises the remarkable research output of California's Institute for Regenerative Medicine (CIRM) during its first seven years, but recommends several changes in oversight that could improve the quality and defensibility of its work. IOM suggests that external scientific reviews and independent oversight of the institute's management could help ameliorate concerns about conflicts of interest and increase transparency.

In a report, the President's Council of Advisors on Science & Technology recommends that the federal government should launch a coordinated effort to boost American agricultural science by increasing public investments.

Recruiting bioscience faculty to universities and investing in R&D infrastructure tops the list of strategies recommended for Iowa to capitalize on a growing bioscience economy. A report commissioned by Innovate Iowa also finds that while significant progress has been made in growing the state's bioscience industry over the last 10 years, declining state funds to build research capacity and provide seed and venture capital remains a challenge for bioscience companies and entrepreneurs to compete regionally and globally.

Although the U.S. has been at the forefront of the life sciences revolution, a lack of sustained federal funding in biomedical research and intensified competition are threatening its global leadership, finds a new report from the Information Technology and Innovation Foundation (ITIF). Another problem for the U.S. is a lack of consistency and predictability in the level of biomedical research funding — particularly through the National Institutes of Health (NIH).

Two common themes emerged in a trio of reports aimed at growing the bioscience sectors in Indiana, New York and Pennsylvania: the need for a sustained financial commitment from the states and the importance of a shared vision and better communication between policymakers and industry leaders. In all three reports, the authors say the payoff is big for the states. The bioscience and life science industries support high-wage jobs and attract significant federal funds.

Indiana